CSL Behring joins pandemic R&D fight with antibody work

Australia’s largest biotech company CSL says it is working on a plasma-based therapy for patients with more severe forms of COVID-19.

CSL Behring Australia, a subsidiary of CSL Limited, said today it would “begin immediate onshore development of an anti-SARS-CoV-2 plasma product with the potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation.”